MicroVue™ SC5b-9 Plus EIA

The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens.


Product Specifications

Citations 97
Specimen

Serum 10 μL, EDTA or Citrated Plasma 50 μL

LLOQ 8.8 ng/mL
ULOQ N/A
Assay Time 2 hours
Cross Reactivity

African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A020
Catalog Number (CE) A029
Size 96 wells/test
Price (USD) $725.00
Price (EURO) 650,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the amount of the SC5b-9 complex in specimens.

Size 96 wells/test
Form

96 well plate with 12 eight-well strips in a resealable foil pouch

Specimen Serum 10 μL, EDTA or Citrated Plasma 50 μL
Limit of Detection (LOD) 3.7 ng/mL
Lower Limit of Quantitation (LLOQ) 8.8 ng/mL
Upper Limit of Quantitation (ULOQ) N/A
Intra Assay 1.6–6.8%
Inter Assay 5.0–13.1%
Standards 5
Controls 2
Sample Values

None

Assay Time 2 hours
Cross Reactivity

African Green Monkey, Baboon, Cynomolgous monkey, Pigtail Monkey, Rabbit, Rhesus monkey

Storage

Store the unopened kit at 2°C to 8°C. Refer to Product Insert for additional storage details.

Background

The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation. Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein, at the C5b-7 stage of assembly forming soluble, non-lytic TCC. For purposes of this document, we refer to all forms of stable Terminal Complement Complex interchangeably as TCC and SC5b-9, recognizing that other complement regulatory proteins, like Clusterin, also form these stable complexes and are detectable in the SC5b-9 Plus assay. The MicroVue SC5b-9 Plus Enzyme Immunoassay measures the concentration of TCC thereby giving an indication of the status of the terminal complement pathway in the specimen. It uses a monoclonal antibody to the C9 ring of TCC to capture the complex. The trapped TCC is subsequently detected with HRP-conjugated antibodies that bind to antigens of the SC5b-9 complex. This test, which provides a rapid, highly specific and quantitative procedure for measuring TCC levels, is designed for investigations studying the role or status of terminal complement pathway activation in numerous research settings, and for monitoring the generation of SC5b-9 complexes in vivo or in vitro.

Citations

Title Year Applications Sample Species Sample Sample Details

Complement activation in patients with neuromyelitis optica

2014

ELISA

Human

Plasma

Neuromyelitis optica

Pentraxin 3 recruits complement factor H to protect against oxidative stress-induced complement and inflammasome overactivation.

2016

ELISA

Human

ARPE-19 Cells

Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.

2017

ELISA

Human

Serum

Diabetes

Complete kinetic follow-up of symptoms and complement parameters during a hereditary angioedema attack.

2017

ELISA

Human

Plasma

Hereditary Angioedema

Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

2018

ELISA

Human

Serum

Microvesicles with heme

A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.

2019

ELISA

Human

Plasma

Chronic Lymphocytic Leukemia

A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity.

2019

ELISA

Human

Serum

Chronic Lymphocytic Leukemia

Clinical Value of Complement Activation Biomarkers in Overt Diabetic Nephropathy

2019

ELISA

Human

Urine

Diabetic nephropathy

Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

2019

ELISA

Human

Plasma

ANCA-AAV

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.

2019

ELISA

Human

Plasma

aHUS

Complement factor H contributes to mortality in humans and mice with bacterial meningitis.

2019

ELISA

Human

CSF

Bacterial meningitis

Complement fragments are biomarkers of antibody-mediated endothelial injury.

2019

ELISA

Human

Plasma

Antibody-mediated endothelial injury

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020

ELISA

Human

Plasma

FSGS

Complement Activation Profile of Patients With Primary Focal Segmental Glomerulosclerosis.

2020

ELISA

Human

Serum

FSGS

Cloaking Silica Nanoparticles with Functional Protein Coatings for Reduced Complement Activation and Cellular Uptake.

2020

ELISA

Human

Serum

SiNP coated proteins

Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy.

2020

ELISA

Human

Plasma

COVID-19

Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis.

2019

ELISA

Human

Urine

FSGS, MN, IgAN, LN, AAV, or MPGN

Complement activation and endothelial perturbation parallel COVID-19 severity and activity.

2020

ELISA

Human

Plasma

COVID-19

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020

ELISA

Human

Serum

Lupus Nephritis, Thrombotic Microangiopathy

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

2020

ELISA

Human

Urine

Lupus Nephritis, Thrombotic Microangiopathy

P-MAPA, a Fungi-Derived Immunomodulatory Compound, Induces a Proinflammatory Response in a Human Whole Blood Model.

2020

ELISA

Human

Plasma

P-MAPA

Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation.

2020

ELISA

Human

Plasma

Thrombotic Microangiopathy - TA

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state.

2021

ELISA

Human

Serum

COVID-19

Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.

2021

ELISA

Human

Glomular Endothelial Cells

Supernatent

CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis

2021

ELISA

Human

Plasma

MPGN

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021

ELISA

Human

Plasma

C3G

von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.

2021

ELISA

Human

Urine

C3G

Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy

2021

ELISA

Human

Plasma

Thrombotic Microangiopathy - TA

Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.

2021

ELISA

Human

Plasma

Eculizumab as a New Treatment for Severe Acute Post-infectious Glomerulonephritis: Two Case Reports.

2021

ELISA

Human

Plasma

Glomerulonephritis

The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.

2021

ELISA

Human

Plasma

Lupus Nephritis

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.

2021

ELISA

Human

Plasma

Cancer, COVID-19

Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.

2021

ELISA

Human

Plasma

COVID-19

Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.

2021

ELISA

Human

Serum

aHUS

Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy.

2021

ELISA

Human

Urine

aHUS

Severe COVID-19 is associated with hyperactivation of the alternative complement pathway.

2021

ELISA

Human

Plasma

COVID-19

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.

2022

ELISA

Human

Plasma

aHUS

C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.

2022

ELISA

Human

Plasma

COVID-19

Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.

2021

ELISA

Human

Plasma

COVID-19

Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

2022

ELISA

Human

Plasma

COVID-19

Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

2022

ELISA

Human

Serum

COVID-19

High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.

2022

ELISA

Human

Plasma

Antiphospholipid syndrome

Mechanism of Borrelia immune evasion by FhbA-related proteins

2022

ELISA

Human

Plasma

Borrelia hermsii

Complement Activation in Patients With Heat-Related Illnesses: Soluble CD59 Is a Novel Biomarker Indicating Severity of Heat-Related Illnesses.

2022

ELISA

Human

Plasma

Heat-related illnesses

Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis.

2022

ELISA

Human

Serum

Myeloperoxidase-ANCA-associated glomerulonephritis

Comparison of Complement Pathway Activation in Autoimmune Glomerulonephritis.

2022

ELISA

Human

Urine

AAV, FSGS, IgAN, MN, and LN

Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.

2022

ELISA

Human

Plasma

COVID-19

Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System.

2022

ELISA

Human

Whole Blood

B. jararaca venom

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.

2022

ELISA

Human

Plasma

Thrombotic Microangiopathy - DI

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.

2022

ELISA

Human

Plasma

Thrombotic Microangiopathy - DI

Effects of Antibody Responses to Pre-Existing Coronaviruses on Disease Severity and Complement Activation in COVID-19 Patients.

2022

ELISA

Human

Plasma

COVID-19

Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.

2022

ELISA

Human

Plasma

Hemodialysis

Complement activation during cardiopulmonary bypass and association with clinical outcomes.

2022

ELISA

Human

Plasma

Cardiopulmonary bypass

Indices of complement activation and coagulation changes in trauma patients

2022

ELISA

Human

Plasma

Trauma

C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome.

2022

ELISA

Human

Plasma

COVID-19

Serum and plasma levels of Ba, but not those of soluble C5b-9, might be affected by renal function in chronic kidney disease patients.

2023

ELISA

Human

Plasma, Serum

Glomerulonephritis

Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury

2009

ELISA

Human

ARPE-19 Cells

Complement C3 serum levels in anorexia nervosa: a potential biomarker for the severity of disease

2011

ELISA

Human

Serum

Heightened measures of immune complex and complement function and immune complex-mediated granulocyte activation in human lymphatic filariasis

2011

ELISA

Human

Plasma

Lymphatic filariasis

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

2012

ELISA

Human

Serum

GEnCs and HUVEC exposed

Elevated Properdin and Enhanced Complement Activation in First-Degree Relatives of South Asian Subjects With Type 2 Diabetes

2012

ELISA

Human

Plasma

Complement activation in pediatric patients with recurrent acute otitis media

2013

ELISA

Human

Ear Fluid (MEE)

Complement activation in pediatric patients with recurrent acute otitis media

2013

ELISA

Human

Serum

Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients.

2013

ELISA

Human

CSF

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.

2013

ELISA

Human

Serum

In Vitro Hematological and In Vivo Vasoactivity Assessment of Dextran Functionalized Graphene

2013

ELISA

Human

Plasma

Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial

2014

ELISA

Human

Serum

Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center

2014

ELISA

Human

Plasma

Lupus Nephritis

Defining the complement biomarker profile of C3 glomerulopathy

2014

ELISA

Human

Plasma

C3G

Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum

2014

ELISA

Human

Serum

SPIO nanoworms

Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome

2015

ELISA

Human

Plasma

Stx-HUS

A serine protease isolated from the bristles of the Amazonic caterpillar, Premolis semirufa, is a potent complement system activator.

2015

ELISA

Human

Serum

Premolis semirufa caterpillar bristle extract

Cerebrospinal fluid inflammatory markers in patients with Listeria monocytogenes meningitis

2014

ELISA

Human

CSF

Listeria meningitis

Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis

2015

ELISA

Human

Plasma

Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness

2015

ELISA

Human

Serum

In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles

2016

ELISA

Human

Serum

Nanoparticles incubated

Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.

2016

ELISA

Human

Serum

Inflammatory Response in Preterm and Very Preterm Newborns with Sepsis

2016

ELISA

Human

Serum

Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking.

2016

ELISA

Human

Serum

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

2016

ELISA

Human

Plasma

Imprime yeast treated

High Levels of Soluble C5b-9 Complex in Dialysis Fluid May Predict Poor Prognosis in Peritonitis in Peritoneal Dialysis Patients

2017

ELISA

Human

Peritoneal dialysis fluid

Brain injury with systemic inflammation in newborns with congenital heart disease undergoing heart surgery

2017

ELISA

Human

Serum

Trauma, newborn brain

Effect of Immobilized Antithrombin III on the Thromboresistance of Polycarbonate Urethane

2017

ELISA

Human

Serum

Immunological response to nitroglycerin-loaded shear-responsive liposomes in vitro and in vivo

2017

ELISA

Human

Serum

Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

2017

ELISA

Human

Plasma

ANCA-AAV

rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs

2018

ELISA

Human

Serum

Fc activation

Venom from Bothrops lanceolatus, a Snake Species Native to Martinique, Potently Activates the Complement System

2018

ELISA

Human

Serum

B. lanceolatus venom

Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura.

2020

ELISA

Human

Plasma

Immune‐mediated thrombotic thrombocytopenic purpura

Sensitivity and Specificity of plasma and urine complement split products as indicators of lupus disease activity

1996

ELISA

Human

Plasma

Systemic Lupus Erythematosus

Decrease in multiple complement protein levels is associated with the development of islet autoimmunity and type 1 diabetes.

2023

ELISA

Human

Plasma

Diabetes

Persistent complement dysregulation with signs of thromboinflammation in active Long Covid.

2023

ELISA

Human

Serum

COVID-19

Decrease in multiple complement proteins associated with development of islet autoimmunity and type 1 diabetes.

2024

ELISA

Human

Plasma

Diabetes, Type 1

Persistent complement dysregulation with signs of thromboinflammation in active Long Covid

2024

ELISA

Human

Serum

COVID-19

Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 Glomerulopathy

2024

ELISA

Human

Plasma

C3G

A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease

2024

ELISA

Human

Urine

FSGS, MCD

Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model

2017

ELISA

Mouse

Serum